SPRUCE BIOSCIENCES INC (SPRB) Stock News
NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD
SPRB Latest News, Press Relases and Analysis
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
Mentions: OTC
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Mentions: OTC
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spruce Biosciences (NASDAQ:SPRB) just reported results for the second quarter o...
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
On Tuesday, Spruce Biosciences, Inc. (NASDAQ:SPRB) revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Congenital adrenal hyperplasia (CAH) is a genetic disease that affects the adrenal glands and prevents the production of hormones like cortisol, aldosterone, and androgens. Also Read: Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disord
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024
SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences Recognized as a Bay Area Best Place to Work
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
